The utility of long non-coding RNA ZEB1-AS1 as a prognostic biomarker in human solid tumors: A meta-analysis

2018 ◽  
Vol 485 ◽  
pp. 14-20 ◽  
Author(s):  
Xue-liang Zuo ◽  
Juan Cai ◽  
Zhi-qiang Chen ◽  
Yao Zhang ◽  
Lin-hu Liang ◽  
...  
2018 ◽  
Vol 481 ◽  
pp. 99-107 ◽  
Author(s):  
Chaojie Liang ◽  
Bing Zhang ◽  
Hua Ge ◽  
Yingchen Xu ◽  
Guangming Li ◽  
...  

2020 ◽  
Author(s):  
Lijun Lei ◽  
Lianbing Sheng ◽  
Lingyuan Wu ◽  
Jiaojing Liu ◽  
Bin Wei ◽  
...  

Abstract Background We performed this meta-analysis to elucidate whether the expression of PlncRNA-1 might serve as an effective prognostic marker for various cancers. Methods We conducted a database search of PubMed, ScienceDirect, Embase, Web of Science and CNKI database (up to Oct 31, 2019). The pooled hazard ratio (HR), odds ratio (OR) and 95% confidence interval (CI) were used to estimate the strength of the relationship between PlncRNA-1 expression and the clinical prognosis of cancer patients. Results The results showed that elevated PlncRNA-1 expression predicted a poor OS with pooled HRs of 1.43 (95% CI: 1.25-1.63, I 2 =63.1%, P=0.004). Likewise, we found that advanced tumour stages were associated with upregulated PlncRNA-1 expression in various cancer types (III–IV vs I–II: OR=2.79, 95% CI: 1.76-4.41, I 2 =0%, P=0.822),patients with high PlncRNA-1 expression might have an increased risk of large tumours (OR=2.03, 95% CI: 1.31-3.14, I 2 =67.1%, P=0.028). Conclusions PlncRNA-1 might be used as a prognostic biomarker and as a tool for the early detection of various tumours.


2018 ◽  
Vol 484 ◽  
pp. 91-98 ◽  
Author(s):  
Chaojie Liang ◽  
Jing Liu ◽  
Hua Ge ◽  
Yingchen Xu ◽  
Guangming Li ◽  
...  

Oncotarget ◽  
2017 ◽  
Vol 8 (37) ◽  
pp. 62454-62462 ◽  
Author(s):  
Peng-Ju Ma ◽  
Qing-Kai Guan ◽  
Lei Meng ◽  
Nan Qin ◽  
Jia Zhao ◽  
...  

Oncotarget ◽  
2017 ◽  
Vol 8 (13) ◽  
pp. 21410-21417 ◽  
Author(s):  
Yang-Hua Fan ◽  
Miao-Jing Wu ◽  
Yuan Jiang ◽  
Minhua Ye ◽  
Shi-Gang Lu ◽  
...  

2018 ◽  
Vol 486 ◽  
pp. 357-368 ◽  
Author(s):  
Chaojie Liang ◽  
Jinghong Zhang ◽  
Hua Ge ◽  
Yingchen Xu ◽  
Shulin Ren ◽  
...  

Medicine ◽  
2019 ◽  
Vol 98 (27) ◽  
pp. e16087 ◽  
Author(s):  
Bo Zou ◽  
Dong Wang ◽  
Kai Xu ◽  
Jian-lin Liu ◽  
Dao-ying Yuan ◽  
...  

Oncotarget ◽  
2016 ◽  
Vol 7 (36) ◽  
pp. 57991-58000 ◽  
Author(s):  
Fang-teng Liu ◽  
Pei-qian Zhu ◽  
Hong-liang Luo ◽  
Yi Zhang ◽  
Cheng Qiu

2018 ◽  
Vol 49 (2) ◽  
pp. 530-544 ◽  
Author(s):  
Ting Zhang ◽  
Dong-ming Wu ◽  
Shi-hua Deng ◽  
Rong Han ◽  
Teng Liu ◽  
...  

Background/Aims: Recent studies have reported the importance of tubulin alpha 4b (TUBA4B), a long non-coding RNA, in the development of several cancers; however, studies on its clinical significance are rare. In the present meta-analysis, we investigated whether TUBA4B can be used as a prognostic biomarker in human cancers. Methods: A comprehensive search was performed in PubMed, Embase, Web of Science, and the Gene Expression Omnibus databases. Hazard ratios from individual studies were calculated and pooled using a random-effects or fix-effects model. The pooled hazard ratio (HR) with 95% confidence interval (CI) was used to evaluate the value of TUBA4B. The expression of TUBA4B was evaluated in lung cancer tissue arrays by fluorescence in situ hybridization assay. Additionally, a sensitivity analysis and Begg’s test were conducted. Results: We found that TUBA4B was significantly correlated with overall survival (OS) (HR = 1.33, 95% CI: 1.16–1.52, P=0.000), disease-free survival (DFS; HR = 1.25, 95% CI: 1.06–1.48, P=0.007), and recurrence-free survival (RFS; HR = 1.42, 95% CI: 1.26–1.60, P=0.000). In addition, TUBA4B was a risk factor for lung cancer (HR = 1.24, 95% CI: 1.03–1.49, P=0.021), colon cancer (HR = 1.67, 95% CI: 1.02–2.74, P=0.042), breast cancer (HR = 1.52, 95% CI: 1.10–2.12, P=0.012), and ovarian cancer (HR = 1.67, 95% CI: 1.18–2.36, P=0.004). Moreover, LncRNA-TUBA4B was significantly lower expression in tumor tissues than normal lung tissues (P< 0.001). The expression of lncRNA-TUBA4B was decreased with the progression of lung cancer stage. A subgroup meta-analysis based on data resource, sample size, region, patient numbers, and tumor type was further performed. Our studies revealed that tumor tissues with low levels of TUBA4B was significantly associated with short OS, DFS, and RFS in cancer patients. Conclusion: The present findings suggest that TUBA4B can be a novel biomarker for the prognosis of various cancers.


Sign in / Sign up

Export Citation Format

Share Document